The Kentucky Society of Addiction Medicine
The Voice of Addiction Medicine in Kentucky
Advocate, Connect, Teach
Addiction is a treatable brain disease.
KYSAM advocates for evidenced based treatment that has been proven effective.
Image from Shutterstock.
Support Our Petition:
Dr. James Patrick Murphy is spearheading an opportunity for stakeholders to sign onto a letter to the Kentucky Board of Medical Licensure (KBML) urging it stop Lnalization of proposed changes to 201 KAR 9:270, a regulation governing the prescribing of buprenorphine for the treatment of opioid use disorder (OUD), and instead form a new workgroup charged with conducting a thorough review of the regulation and recommending revisions through a transparent process.
The current proposed changes risk perpetuating severe harm during a rapidly evolving addiction and overdose crisis, are inconsistent with evidence-based practice, create new treatment barriers, and may even worsen the addiction and overdose crisis in Kentucky.
By signing this form, you are indicating you would like your signature on the letter. See link below.
Please forward this widely to stakeholders in Kentucky and urge them to also sign and pass along.
Please also note you will also be subject to the following disclaimer if you sign the letter:
"The views expressed herein are those of the individual signatories and do not necessarily represent the views of their institutions or organizations."
Follow Link Here: (copy and paste into your browser) https://docs.google.com/forms/d/e/1FAIpQLSch4rDEK0RY9YQ5L--Wq_AwFmK-8IJXnvi-zzkQ07jepsiFsg/viewform
To view the proposed changes click here:
Check out the NEWS Section for an update on our progress!
The Kentucky Society of Addiction Medicine (KYSAM) is the Kentucky Chapter of the American Society of Addiction Medicine (ASAM). ASAM was founded in 1954 and represents over 7000 physicians, clinicians, and associated professionals in the field of addiction medicine.
The mission of KYSAM is to provide a medium for physicians and medical trainees with special interests in Addiction Medicine practicing in the state of Kentucky to meet and address issues of mutual interest.
The Purposes of The Society are: to enable networking with colleagues in Addiction Medicine, to provide closer liaison between members and the national activities of ASAM, to provide liaison to other physicians and physician societies regarding Addiction Medicine issues, to increase public awareness in about the existence and vitality of the physician specialty of Addiction Medicine, to increase public awareness of problems related to addiction and substance use, to promote professionalism in the delivery of services to patients with problems which result from addiction and/or substance use, and to be a physician resource for state and national public policy issues that affect Addiction Medicine services and patients with addiction and/or substance use disorders.
The Goals of the Society are to provide: a forum for sharing of ideas between physicians interested in Addiction Medicine, especially regarding clinical management strategies and strategies for interfacing with payer organizations and health care systems; a vehicle for increased professionalism and higher quality information, prevention, training, and treatment regarding addiction and substance use disorders; Page 3 an enhancement of knowledge and attitudes among citizens and institutions about the primary nature of the disease of addiction and substance use disorders; a channel for Kentucky input into national standards of care in Addiction Medicine; and a channel for Kentucky input into health care reform initiatives.
Prescribe Buprenorphine to Treat Opioid Use Disorder
As of June 2023, Section 1262 of the Consolidated Appropriations Act (also known as the Omnibus Bill) removed the federal requirement to have a waiver to prescribe buprenorphine for treatment of OUD. This means that any prescriber with a DEA registration in good standing can prescribe buprenorphine for the treatment of OUD. The Medication Access and Training Expansion (MATE) Act requires prescribers to complete a one-time requirement of eight hours of training on the treatment and management of patients with opioid or other substance use disorders in order to apply or renew their DEA registration to prescribed controlled substances.
Useful Links:
Kentucky 2023 Drug Overdose Fatality Report, Kentucky Office of Drug Control Policy https://governor.ky.gov/attachments/2023-Drug-Overdose-Fatality-Report.pdf
2. CDC National Center for Health Statistics, Drug Overdose Mortality by State (2022) https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm
3. CDC National Center for Health Statistics, Drug Overdose Deaths https://www.cdc.gov/nchs/hus/topics/drug-overdose-deaths.htm
4. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. American Journal of Preventive Medicine. Vol 65, Issue 1, P19-29, July 2023 https://www.ajpmonline.org/article/S0749-3797(23)00052-1/abstract#:~:text=Buprenorphine%20treatment%20after%20nonfatal%20opioid,of%20opioid%2Dinvolved%20overdose%20death
5. Lei, Feitong PhD; Lofwall, Michelle R. MD; McAninch, Jana MD, MPH, MS; Adatorwovor, Reuben PhD; Slade, Emily PhD; Freeman, Patricia R. PhD; Moga, Daniela C. MD, PhD; Dasgupta, Nabarun PhD, MPH; Walsh, Sharon L. PhD; Vickers-Smith, Rachel PhD; Slavova, Svetla PhD. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality. Journal of Addiction Medicine 18(3):p 319-326, 5/6 2024. | DOI: 10.1097/ADM.0000000000001300 https://journals.lww.com/journaladdictionmedicine/fulltext/2024/05000/higher_first_30_day_dose_of_buprenorphine_for.15.aspx
6. Improving Access to Opioid Use Disorder Treatment in Kentucky. The Pew Charitable Trusts https://odcp.ky.gov/Resources/Documents/Pew%20Kentucky%20Memo%20FINAL.pdf
7. Buprenorphine Prescribing Requirements and Limitations. Prescription Drug Abuse Policy System https://pdaps.org/datasets/buprenorphine-prescribing-requirements-and-limitations
8. ASAM Public Policy Statement on the Regulation of Office-Based Opioid Treatment https://www.asam.org/docs/default-source/public-policy-statements/statement-on-regulation-of-obot.pdf
KBML Regulations for Prescribing Controlled Substances:https://apps.legislature.ky.gov/law/kar/titles/201/009/260/KBML
KBML Regulations for Prescribing Buprenorphine: https://apps.legislature.ky.gov/law/kar/titles/201/009/270/KBML
Kentucky Controlled Substances Schedules II-V: https://www.chfs.ky.gov/agencies/os/oig/dai/deppb/Documents/KentuckyScheduledDrugList.pdf
Substance Abuse and Mental Health Services Administration (SAMHSA) Practitioner Training: https://www.samhsa.gov/practitioner-training
Our KYSAM Newsletter: https://conta.cc/3Cbx9Sf
Educational resources: https://kyopen.uky.edu. CE credit available. https://www.cecentral.com/kyopen
